ES2148224T3 - Formulacion de rapamicina para inyecciones intravenosas. - Google Patents
Formulacion de rapamicina para inyecciones intravenosas.Info
- Publication number
- ES2148224T3 ES2148224T3 ES93908637T ES93908637T ES2148224T3 ES 2148224 T3 ES2148224 T3 ES 2148224T3 ES 93908637 T ES93908637 T ES 93908637T ES 93908637 T ES93908637 T ES 93908637T ES 2148224 T3 ES2148224 T3 ES 2148224T3
- Authority
- ES
- Spain
- Prior art keywords
- rapamycin
- solution
- weight percent
- polyethylene glycol
- percent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE PRESENTA UNA SOLUCION DE RAPAMICIN INYECTABLE, ACUOSA QUE SE OBTIENE MEDIANTE UN PROCESO QUE COMPRENDE LA MEZCLA DE ENTRE UN 0.1 Y UN 10% DEL PESO DE UNA SOLUCION CONCENTRADA DE RAPAMICIN EN N,NDIMETILACETAMIDO, A CONCENTRACIONES DEL RAPAMICIN QUE OSCILAN ENTRE 0.25 MG/ML Y 100 MG/ML, CON UNA SOLUCION DILUYENTE QUE COMPRENDE ENTRE UN 0.1 Y UN 10% DEL PESO DE AGUA DE UNO O MAS ESTERES DE SORBITAN DE POLIOXIETILENO, ENTRE UN 10 Y 60% DEL PESO DE GLICOL DE POLIETILENO 200 O 300 O AMBOS Y ENTRE UN 36 Y UN 90% DEL VOLUMEN DE AGUA, EN DONDE LA CONCENTRACION DEL RAPAMICIN EN LA SOLUCION COMBINADA OSCILA ENTRE 0.05 MG/ML Y 5.0 MG/ML.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86053092A | 1992-03-30 | 1992-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2148224T3 true ES2148224T3 (es) | 2000-10-16 |
Family
ID=25333426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES93908637T Expired - Lifetime ES2148224T3 (es) | 1992-03-30 | 1993-03-29 | Formulacion de rapamicina para inyecciones intravenosas. |
Country Status (21)
Country | Link |
---|---|
US (1) | US5530006A (es) |
EP (1) | EP0633783B1 (es) |
JP (1) | JPH07505628A (es) |
KR (1) | KR950700750A (es) |
AT (1) | ATE193652T1 (es) |
AU (1) | AU681579B2 (es) |
CA (1) | CA2132636C (es) |
DE (1) | DE69328829T2 (es) |
DK (1) | DK0633783T3 (es) |
ES (1) | ES2148224T3 (es) |
GR (1) | GR3034293T3 (es) |
HU (2) | HUT70947A (es) |
LV (1) | LV12657B (es) |
MX (1) | MX9301740A (es) |
NZ (1) | NZ251628A (es) |
PH (1) | PH30923A (es) |
PT (1) | PT633783E (es) |
SG (1) | SG49652A1 (es) |
TW (1) | TW427903B (es) |
WO (1) | WO1993019763A1 (es) |
ZA (1) | ZA932224B (es) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111003A0 (en) * | 1993-09-30 | 1994-11-28 | American Home Prod | Multi-component oral rapamycin formulation |
US5616588A (en) * | 1993-09-30 | 1997-04-01 | American Home Products Corporation | Rapamycin formulation for IV injection |
CA2175215C (en) * | 1993-11-19 | 2008-06-03 | Yat Sun Or | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
US5527907A (en) * | 1993-11-19 | 1996-06-18 | Abbott Laboratories | Macrolide immunomodulators |
FR2736550B1 (fr) * | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
US5780462A (en) * | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
WO1997025714A1 (fr) * | 1996-01-08 | 1997-07-17 | Kabushiki Kaisha Toshiba | Support d'enregistrement de donnees, procede d'enregistrement et dispositif de reproduction |
US5989591A (en) * | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
US5985325A (en) * | 1997-06-13 | 1999-11-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
US6682758B1 (en) | 1998-12-22 | 2004-01-27 | The United States Of America As Represented By The Department Of Health And Human Services | Water-insoluble drug delivery system |
AU2001247401A1 (en) * | 2000-03-14 | 2001-09-24 | Genetics Institute Inc. | Therapies that improve graft survival, using antibodies against a b7 antigen |
WO2001068133A1 (en) * | 2000-03-14 | 2001-09-20 | Genetics Institute, Inc. | Use of rapamycin and agents that inhibit b7 activity in immunomodulation |
US6670355B2 (en) * | 2000-06-16 | 2003-12-30 | Wyeth | Method of treating cardiovascular disease |
MXPA03002258A (es) | 2000-09-19 | 2003-06-24 | Wyeth Corp | Esteres de rapamicina solubles en agua. |
US6399625B1 (en) | 2000-09-27 | 2002-06-04 | Wyeth | 1-oxorapamycins |
US6399626B1 (en) | 2000-10-02 | 2002-06-04 | Wyeth | Hydroxyesters of 7-desmethylrapamycin |
US6440991B1 (en) | 2000-10-02 | 2002-08-27 | Wyeth | Ethers of 7-desmethlrapamycin |
JP4547911B2 (ja) | 2002-02-01 | 2010-09-22 | アリアド・ファーマシューティカルズ・インコーポレイテッド | リン含有化合物およびその用途 |
BR0313024A (pt) * | 2002-07-30 | 2005-07-12 | Wyeth Corp | Formulações parenterais contendo um hidroxiéster de rapamicina |
PT1539157E (pt) | 2002-09-18 | 2013-10-04 | Univ Pennsylvania | Rapamicina para utilização na inibição ou prevenção de neovascularização coroidal |
EP1682132A1 (en) * | 2003-09-18 | 2006-07-26 | Macusight, Inc. | Transscleral delivery |
FR2862872A1 (fr) * | 2003-12-02 | 2005-06-03 | Palbian Snc | Composition a l'etat aqueux pour l'application perfusable d'un principe actif, notamment pharmacologique tel que le paracetamol. |
US20050220835A1 (en) * | 2004-03-30 | 2005-10-06 | Jayaraman Ramesh B | Agent eluting bioimplantable devices and polymer systems for their preparation |
US7846940B2 (en) | 2004-03-31 | 2010-12-07 | Cordis Corporation | Solution formulations of sirolimus and its analogs for CAD treatment |
US8003122B2 (en) | 2004-03-31 | 2011-08-23 | Cordis Corporation | Device for local and/or regional delivery employing liquid formulations of therapeutic agents |
WO2006115509A2 (en) | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Small molecule immunopotentiators and assays for their detection |
EP1848431B1 (en) | 2005-02-09 | 2016-02-03 | Santen Pharmaceutical Co., Ltd. | Liquid formulations for treatment of diseases or conditions |
US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
JP2008535858A (ja) * | 2005-04-07 | 2008-09-04 | ニトロメッド インコーポレーティッド | 心不全における遺伝リスク、すなわちnos3の遺伝子変異の影響の評価方法 |
CA2624933A1 (en) * | 2005-10-04 | 2007-04-12 | Nitromed, Inc. | Methods for treating respiratory disorders |
EP1945030A4 (en) * | 2005-10-04 | 2009-10-21 | Nitromed Inc | ASSESSING GENETIC RISK IN CARDIAC INSUFFICIENCIES: THE IMPACT OF THE GENETIC VARIATION OF GLY389ARG POLYMORPHISM OF THE BETA ADRENERGIC RECEPTOR 1 |
WO2007092620A2 (en) | 2006-02-09 | 2007-08-16 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
WO2007097951A2 (en) * | 2006-02-17 | 2007-08-30 | Nitromed, Inc. | Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate |
ES2563288T3 (es) | 2006-03-23 | 2016-03-14 | Santen Pharmaceutical Co., Ltd | Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular |
CA2646266A1 (en) * | 2006-04-10 | 2007-10-25 | Nitromed, Inc. | Assessment of heart failure risk using genetic assessment of g-protein beta-3 subunit polymorphism |
EP1938800A1 (en) | 2006-12-06 | 2008-07-02 | Ranbaxy Laboratories Limited | Sirolimus nanodispersion |
US8440185B2 (en) * | 2006-12-26 | 2013-05-14 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
EP2109455A2 (en) * | 2006-12-27 | 2009-10-21 | The Johns Hopkins University | Compositions and methods for stimulating an immune response |
US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
US8420110B2 (en) | 2008-03-31 | 2013-04-16 | Cordis Corporation | Drug coated expandable devices |
US8409601B2 (en) | 2008-03-31 | 2013-04-02 | Cordis Corporation | Rapamycin coated expandable devices |
US20100098770A1 (en) * | 2008-10-16 | 2010-04-22 | Manikandan Ramalingam | Sirolimus pharmaceutical formulations |
IN2012DN02753A (es) | 2009-08-31 | 2015-09-18 | Amplimmune Inc | |
KR101267813B1 (ko) * | 2009-12-30 | 2013-06-04 | 주식회사 삼양바이오팜 | 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 |
WO2011135580A2 (en) | 2010-04-28 | 2011-11-03 | Cadila Healthcare Limited | Pharmaceutical compositions of sirolimus |
WO2012092421A2 (en) | 2010-12-30 | 2012-07-05 | Surmodics, Inc. | Composition for intravascular delivery of therapeutic composition |
EP3939572B1 (en) | 2012-04-12 | 2024-03-27 | Yale University | Vehicles for controlled delivery of different pharmaceutical agents |
EP2934575A2 (en) | 2012-12-19 | 2015-10-28 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
US20160146806A1 (en) | 2013-05-17 | 2016-05-26 | Amplimmune, Inc. | Receptors for b7-h4 |
EP3473253A1 (en) | 2014-10-29 | 2019-04-24 | University Of Maryland | Methods of treating age-related symptoms in mammals and compositions therefor |
ES2957882T3 (es) | 2015-09-04 | 2024-01-29 | Univ Yale | Nanocomposiciones de ácidos biliares poliméricos dirigidas al páncreas y al colon |
US20190117799A1 (en) | 2016-04-01 | 2019-04-25 | The Brigham And Women's Hospital, Inc. | Stimuli-responsive nanoparticles for biomedical applications |
RU2757394C2 (ru) | 2016-08-03 | 2021-10-14 | Нексткьюр, Инк. | Композиции и способы для модуляции передачи сигнала lair |
EP4360714A2 (en) | 2016-09-21 | 2024-05-01 | Nextcure, Inc. | Antibodies for siglec-15 and methods of use thereof |
US11390675B2 (en) | 2016-09-21 | 2022-07-19 | Nextcure, Inc. | Antibodies for Siglec-15 and methods of use thereof |
WO2019217552A1 (en) | 2018-05-09 | 2019-11-14 | Yale University | Particles for spatiotemporal release of agents |
US20210115378A1 (en) | 2018-05-09 | 2021-04-22 | Yale University | Compositions and systems for ex vivo cell modulation and methods of use thereof |
EP3911302A1 (en) | 2019-01-17 | 2021-11-24 | Georgia Tech Research Corporation | Drug delivery systems containing oxidized cholesterols |
EP4167958A1 (en) | 2020-06-19 | 2023-04-26 | Yale University | Polymeric bile acid ester nanoparticles comprising an immunomodulator agent to induce antigen-specific tolerance |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3627886A (en) * | 1968-04-15 | 1971-12-14 | Hoffmann La Roche | Methods of solubilizing coumermycin employing urea, dimethylacetamide or mixtures thereof |
ZA737247B (en) * | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
AU543727B2 (en) * | 1980-06-02 | 1985-05-02 | Ayerst Mckenna & Harrison Inc. | Injectable composition of rapamycin |
US4707470A (en) * | 1985-05-17 | 1987-11-17 | Smithkline Beckman Corporation | Polyene antibiotic emulsion formulation |
US5202241A (en) * | 1988-09-09 | 1993-04-13 | Gruppo Lepetit S.P.A. | Antibiotic GE 2270 |
KR0177158B1 (ko) * | 1990-03-01 | 1999-03-20 | 후지사와 도모기찌로 | 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제 |
-
1993
- 1993-03-29 AT AT93908637T patent/ATE193652T1/de not_active IP Right Cessation
- 1993-03-29 DK DK93908637T patent/DK0633783T3/da active
- 1993-03-29 JP JP5517594A patent/JPH07505628A/ja active Pending
- 1993-03-29 ZA ZA932224A patent/ZA932224B/xx unknown
- 1993-03-29 MX MX9301740A patent/MX9301740A/es not_active IP Right Cessation
- 1993-03-29 PH PH45950A patent/PH30923A/en unknown
- 1993-03-29 ES ES93908637T patent/ES2148224T3/es not_active Expired - Lifetime
- 1993-03-29 DE DE69328829T patent/DE69328829T2/de not_active Expired - Fee Related
- 1993-03-29 WO PCT/US1993/002907 patent/WO1993019763A1/en active IP Right Grant
- 1993-03-29 NZ NZ251628A patent/NZ251628A/en unknown
- 1993-03-29 CA CA002132636A patent/CA2132636C/en not_active Expired - Fee Related
- 1993-03-29 PT PT93908637T patent/PT633783E/pt unknown
- 1993-03-29 AU AU39391/93A patent/AU681579B2/en not_active Ceased
- 1993-03-29 HU HU9402821A patent/HUT70947A/hu unknown
- 1993-03-29 EP EP93908637A patent/EP0633783B1/en not_active Expired - Lifetime
- 1993-03-29 SG SG1996002833A patent/SG49652A1/en unknown
- 1993-03-31 TW TW082102409A patent/TW427903B/zh not_active IP Right Cessation
-
1994
- 1994-03-07 US US08/207,325 patent/US5530006A/en not_active Expired - Lifetime
- 1994-09-28 KR KR1019940703368A patent/KR950700750A/ko not_active IP Right Cessation
-
1995
- 1995-06-28 HU HU95P/P00517P patent/HU211841A9/hu unknown
-
2000
- 2000-08-31 GR GR20000401980T patent/GR3034293T3/el not_active IP Right Cessation
-
2001
- 2001-03-06 LV LV010033A patent/LV12657B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU3939193A (en) | 1993-11-08 |
LV12657A (lv) | 2001-05-20 |
KR950700750A (ko) | 1995-02-20 |
PT633783E (pt) | 2000-11-30 |
HU211841A9 (en) | 1995-12-28 |
EP0633783B1 (en) | 2000-06-07 |
HU9402821D0 (en) | 1994-12-28 |
JPH07505628A (ja) | 1995-06-22 |
DE69328829D1 (de) | 2000-07-13 |
EP0633783A1 (en) | 1995-01-18 |
DK0633783T3 (da) | 2000-09-25 |
ATE193652T1 (de) | 2000-06-15 |
WO1993019763A1 (en) | 1993-10-14 |
SG49652A1 (en) | 1998-06-15 |
HUT70947A (en) | 1995-11-28 |
GR3034293T3 (en) | 2000-12-29 |
CA2132636C (en) | 2002-12-17 |
DE69328829T2 (de) | 2000-10-12 |
NZ251628A (en) | 1996-07-26 |
PH30923A (en) | 1997-12-23 |
MX9301740A (es) | 1993-09-01 |
ZA932224B (en) | 1994-09-29 |
LV12657B (lv) | 2001-09-20 |
US5530006A (en) | 1996-06-25 |
CA2132636A1 (en) | 1993-10-14 |
AU681579B2 (en) | 1997-09-04 |
TW427903B (en) | 2001-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2148224T3 (es) | Formulacion de rapamicina para inyecciones intravenosas. | |
ES2123101T3 (es) | Formulacion de rapamicina para inyeccion intravenosa. | |
ES2123721T3 (es) | Formulaciones de rapamicina para inyecciones por via intravenosa. | |
ES2173124T3 (es) | Composicion de dermatano sulfato utilizado como antitrombotico. | |
PE20000018A1 (es) | Composiciones farmaceuticas a base de dalfopristina y de quinupristina y su preparacion | |
MX9301116A (es) | Derivados de dioxolano. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 633783 Country of ref document: ES |